0001209191-21-016077.txt : 20210302 0001209191-21-016077.hdr.sgml : 20210302 20210302164105 ACCESSION NUMBER: 0001209191-21-016077 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210227 FILED AS OF DATE: 20210302 DATE AS OF CHANGE: 20210302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Akinsanya Karen CENTRAL INDEX KEY: 0001797672 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39206 FILM NUMBER: 21704413 MAIL ADDRESS: STREET 1: SCHRODINGER, INC. STREET 2: 120 WEST 45TH STREET, 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Schrodinger, Inc. CENTRAL INDEX KEY: 0001490978 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 954284541 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 120 WEST 45TH STREET STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 503-299-1150 MAIL ADDRESS: STREET 1: 120 WEST 45TH STREET STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-27 0 0001490978 Schrodinger, Inc. SDGR 0001797672 Akinsanya Karen C/O SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR NEW YORK NY 10036 0 1 0 0 See Remarks Stock Option (right to buy) 102.48 2021-02-27 4 A 0 80000 0.00 A 2031-02-27 Common Stock 80000 80000 D The option was granted on February 27, 2021. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 27, 2022 and the remainder are scheduled to vest in equal monthly installments through February 27, 2025. EVP, Chief Biomedical Scientist, Head of Discovery R&D /s/ Donald Shum, as attorney-in-fact for Karen Akinsanya 2021-03-02